We need to remember that GBM is a solid tumour cancer. Something that CarT has not been able to treat. Any sign of efficacy hereis ground breaking stuff.
There is no SOC for GBM except surgery, and that is only applicable to a small cohort of patients. Again, any sign of efficacy is ground breaking.
Life expectancy of GBM patients is normally measured in months. Any statistical extension is Again ground breaking.
Any or all of the above would allow a fast track approval. Safety so far has been good. Under new fast track rules, drugs can be approved for sale (if certain conditions are met) while the fast track trial is underway.
The Market cap now by no means reflects the GBM drug alone, and then wr have NK and cd17 drugs.
Huge potential upside if you are willing and able to wait
CHM Price at posting:
7.6¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)